Результаты поиска

A Diet Rich in Fish Oil and Leucine Ameliorates Hypercalcemia in Tumour-Induced Cachectic Mice.

BACKGROUND: Dietary supplementation with leucine and fish oil rich in omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) has previously been shown to reduce cachexia-related outcomes in C26 tumour-bearing mice. To further explore associated processes and mechanisms we investigated changes in plasma Ca2+ levels, the involvement of parathyroid hormone related protein (PTHrP), and its possible interactions with cyclooxygenase 2 (COX-2). METHODS: CD2F1 mice were subcutaneously inoculated with C26 adenocarcinoma cells or sham treated and divided in: (1) controls, (2) tu

Совпадение в полном тексте источника
… As a positive control, the specific COX-2 inhibitor celecoxib (CXB) was used. Results showed that DHA was not able to reduce PGE-2 production in C26 cells where CXB reduced PGE-2 levels with 73% at a dose of 0.01 μM, as seen in Figure 4 A,B. … Supplementation for 24h was performed with different concentrations of either docosahexaenoic acid (DHA, 22:6 n-3 ; Sigma-Aldrich, Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany), eicosapentaenoic acid (EPA, 20:5 n-3 ; Sigma-Aldrich Chemie GmbH), leucine (Sigma-Aldrich Chemie GmbH), or celecoxib (CXB …

Radiologically Guided Renal Artery Embolization with an Amplatzer Vascular Plug as a Rescue Therapy for Refractory Nephrotic Syndrome in AL-Amyloidosis.

Nephrotic syndrome is common in immunoglobulin light-chain (AL) amyloidosis and successful therapy may pose a challenge. We report the case of a 63-year-old patient with severe nephrotic syndrome due to primary renal AL-amyloidosis with well-preserved renal function at first presentation. Therapy with high dose steroids, loop diuretics, and ACE-inhibitors did not affect his proteinuria and he was seriously disabled because of symptomatic orthostatic hypotension and anasarca. With the patient's informed consent, medical nephrectomy was tried with nonsteroidal-anti-inflammatory drugs (NSAIDs), c

Совпадение в полном тексте источника
… Medical nephrectomy to reduce proteinuria was started with initially Celecoxib (100 mg bid) due to unchanged proteinuria additionally with cyclosporine (200mg bid). …

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management.

Acute generalized exanthematous pustulosis (AGEP) is a rare, acute, severe cutaneous adverse reaction mainly attributed to drugs, although other triggers, including infections, vaccinations, ingestion of various substances, and spider bites, have also been described. AGEP is characterized by the development of edema and erythema followed by the eruption of multiple punctate, non-follicular, sterile pustules and subsequent desquamation. AGEP typically has a rapid onset and prompt resolution within a few weeks. The differential diagnoses for AGEP are broad and include infectious, inflammatory, a

Совпадение в полном тексте источника
… A number of other drugs have also been reported in the literature, including analgesics and anti-inflammatories, such as paracetamol, celecoxib, ibuprofen, piroxicam, prednisolone, topical mephenesin balm, transdermal ketoprofen, and topical morphine [ 112 – 122 ]. … Acute generalized exanthematous pustulosis induced by celecoxib. J Cutan Pathol. 2016;43(1):80–81. doi: 10.1111/cup.12604. 115. Belz D, Persa OD, Haese S, Hunzelmann N. Acute generalized exanthematous pustulosis caused by ibuprofen-Diagnosis confirmed by patch testing. …

Chemoprevention of colorectal cancer: systematic review and economic evaluation.

BACKGROUND: Colorectal cancer (CRC) is the third most common cancer in the UK: incidence increases with age, median age at diagnosis being o … sults of the health economic analysis should be interpreted with caution. CONCLUSIONS: Aspirin and celecoxib may reduce recurrence of adenomas and incidence of advanced adenomas in individuals with an increased risk of CRC and calcium may reduce recurrence of adenomas in this group. COX-2 inhibitors may decrease polyp number in patients with FAP. There is …

Drug Repurposing for Cancer Treatment: A Comprehensive Review.

Cancer ranks among the primary contributors to global mortality. In 2022, the global incidence of new cancer cases reached about 20 million, while the number of cancer-related fatalities reached 9.7 million. In Saudi Arabia, there were 13,399 deaths caused by cancer and 28,113 newly diagnosed cases of cancer. Drug repurposing is a drug discovery strategy that has gained special attention and implementation to enhance the process of drug development due to its time- and money-saving effect. It involves repositioning existing medications to new clinical applications. Cancer treatment is a therap

Совпадение в полном тексте источника
… Diclofenac has been found to slow pancreatic tumor growth, while the selective COX-2 inhibitor, celecoxib, inhibits breast cancer cell proliferation and tumor formation. … Celecoxib, a COX-2 inhibitor, in combination with zametaxel did not improve survival rates in advanced PC patients. However, docetaxel and zaetaxel significantly improved prognosis in PC patients. …

Pain in blood cancers.

Patients with blood-related cancers (BRC) suffer from a substantial symptom burden, including several pain syndromes sustained by different causes and pathogenetic mechanisms. So, with regard to pain, a multifaceted clinical scenario may be observed in this setting. Indeed, pain may be correlated to disease itself, to disease-associated complications, to iatrogenic causes or may be due to unrelated clinical conditions. A close diagnostic procedure for the assessment of the underlying causes of the pain and of its pathogenetic mechanisms may direct the treatment approach which should be based o

Совпадение в полном тексте источника
… In this regard, although no studies on the use of these agents in the setting of BRC have been reported until now, celecoxib has been reported as effective in treating chronic synovitis and joint pain in hemophiliacs.[ 58 ] However, several reports have pointed at the cardiovascular and renal adverse … doses of transdermal fentanyl in opioid-naive patients with cancer pain Curr Med Res Opin 2010 26 2765 8 21034376 10.1185/03007995.2010.532545 57 Mercadante S Malignant bone pain: Pathophysiology and treatment Pain 1997 69 1 18 9060007 10.1016/s0304-3959(96)03267-8 58 Rattray B Nugent DJ Young G Celecoxib …

Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design.

Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels of circulating tumour cells (CTCs), the efficacy of standard treatment methods is insufficient and results in treatment failure and reduced patient survival. CTCs are seen not only as an isolated phenomenon but also a key inherent part of the formation of metastasis and a key factor in cancer death.

Совпадение в полном тексте источника
… Wang et al. found that celecoxib (a selective inhibitor of cyclooxygenase 2 (COX-2)) induces EMT of NSCLC cells via upregulation of MEK-ERK signalling. [ 37 ] This fact could explain the failure of celecoxib in clinical trials [ 38 , 39 , 40 ]. …

Историческое развитие иммуноэндокринных концепций психических расстройств и их терапии.

Отношения между центральной нервной, иммунной и эндокринной системами являются предметом психиатрических исследований, особенно в области депрессии и шизофрения. У поля длинные предтечи. Наблюдаемые явления, связанные с этими отношениями, восходят к неолитической эпохе. Теории иммуноэндокринной системы в самом широком смысле записаны в древности. В 19th Крепелин и Вагнер-Джаурег сообщили о первых клинических наблюдениях у пациентов психиатрических учреждений. Von Bestow, Эддисон и Кушинг описали психические симптомы у пациентов, страдающих эндокринными заболеваниями. :: 20th откровение века с

Совпадение в полном тексте источника
… So far in particular downregulating cyclooxygenase-2 (Cox-2) has been proposed and indeed first tests of the Cox-2 inhibitor Celecoxib applied as an add-on to conventional antipsychotic treatment have meanwhile shown promising results [ 127 ]. … Another inhibitor of pro-inflammatory cytokines, namely the COX-2 inhibitor celecoxib, has been tested in depressive patients as an add-on therapy together with antidepressant reboxetine. …

Bilateral Knee Effusions Secondary to Zoledronic Acid Infusion.

Intravenous zoledronic acid is an established and generally well tolerated form of antiresorptive therapy for osteoporosis. Although mild arthralgias are a well-documented manifestation of the acute phase response to intravenous bisphosphonates, more severe musculoskeletal reactions manifesting as debilitating pain and joint effusions have been rarely documented in the current literature. In this case report, we discuss the case of a 55-year-old woman who developed severe painful bilateral knee effusions within 1 week of her first zoledronic acid infusion for osteoporosis. Prescribing physicia

Совпадение в полном тексте источника
… Symptomatic treatment was initiated with the use of nonsteroidal anti-inflammatory agents (celecoxib 100 mg twice daily). She did not respond to symptomatic treatment, with persistent pain and re-accumulation of the right knee effusion within 24 hours. …

Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs.

ObjectiveTo determine the exact role of sodium channel proteins in migration, invasion and metastasis and understand the possible anti-invasion and anti-metastatic activity of repurposed drugs with voltage gated sodium channel blocking properties.Material and methodsA review of the published medical literature was performed searching for pharmaceuticals used in daily practice, with inhibitory activity on voltage gated sodium channels. For every drug found, the literature was reviewed in order to define if it may act against cancer cells as an anti-invasion and anti-metastatic agent and if it w

Совпадение в полном тексте источника
… The same effect has been observed with older pharmaceuticals like aspirin 8 , not-as-old pharmaceuticals such as celecoxib 6 , 9 ; new pharmaceuticals like ticagrelor 10 , as well as with more sophisticated molecules like dasatinib and ponatinib 6 or ultrasophisticated drugs, like polymeric plerixafor … Curr Opin Oncol. 2014 ; 26 ( 4 ): 441 – 7 . 10.1097/CCO.0000000000000098 24840525 9 Li WW Long GX Liu DB : Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. …

Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting both upper and lower motor neurons. ALS is classically characterized by painless progressive weakness, causing impaired function of limbs, speech, swallowing, and respiratory function. The disease is fatal within 2-4 years, often the result of respiratory failure. The pathologic hallmark for a majority of ALS cases is aberrant cytoplasmic accumulations of the nuclear protein TAR-DNA binding protein (TDP-43). A total of 10-15% of ALS can be attributed to a single gene mutation, known as genetic or "familia

Совпадение в полном тексте источника
… Disease-Modifying Treatments Pending Regulatory Approval Three additional agents, masitinib, co-formulated ciprofloxacin and celecoxib (marketed as PrimeC), and debamestrocel-MSC-NTF (marketed as NurOwn), are notable due to requests for regulatory opinions [ 168 – 170 ]. … Co-formulated ciprofloxacin and celecoxib is a combination of ciprofloxacin and celecoxib, thought to act synergistically to regulate inappropriate microRNA processing and reduce inflammation [ 172 ]. …

Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles.

Cancer is the leading cause of death globally, and conventional treatments have limited efficacy with severe side effects. The use of nanotechnology has the potential to reduce the side effects of drugs by creating efficient and controlled anticancer drug delivery systems. Nanoparticles (NPs) used as drug carriers offer several advantages, including enhanced drug protection, biodistribution, selectivity and, pharmacokinetics. Therefore, this review is devoted to various organic (lipid, polymeric) as well as inorganic nanoparticles based on different building units and providing a wide range of

Cancer stem cell impact on clinical oncology.

Cancer is a widespread worldwide chronic disease. In most cases, the high mortality rate from cancer correlates with a lack of clear symptoms, which results in late diagnosis for patients, and consequently, advanced tumor disease with poor probabilities for cure, since many patients will show chemo- and radio-resistance. Several mechanisms have been studied to explain chemo- and radio-resistance to anti-tumor therapies, including cell signaling pathways, anti-apoptotic mechanisms, stemness, metabolism, and cellular phenotypes. Interestingly, the presence of cancer stem cells (CSCs), which are

Совпадение в полном тексте источника
… One such drug is Celecoxib, a non-steroidal anti-inflammatory drug that inhibits β-catenin signaling by cyclo-oxygenase (commonly known as COX)-dependent and COX-independent mechanisms[ 116 ]. … downregulates CD133 expression through inhibition of the Wnt signaling pathway in colon cancer cells Cancer Invest 2013 31 97 102 23245395 10.3109/07357907.2012.754458 120 Egashira I Takahashi-Yanaga F Nishida R Arioka M Igawa K Tomooka K Nakatsu Y Tsuzuki T Nakabeppu Y Kitazono T Celecoxib and 2,5 …

Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.

Experimental data indicate that several pharmacological agents that have long been used for the management of various diseases unrelated to cancer exhibit profound in vitro and in vivo anticancer activity. This is of major clinical importance, since it would possibly aid in reassessing the therapeutic use of currently used agents for which clinicians already have experience. Further, this would obviate the time-consuming process required for the development and the approval of novel antineoplastic drugs. Herein, both pre-clinical and clinical data concerning the antineoplastic function of dist

Совпадение в полном тексте источника
… COX-2, however, can be selectively targeted by a specific class of NSAIDs including celecoxib and etoricoxib, the so-called coxibs. … system inhibits growth of colorectal cancer liver metastases in the regenerating liver Clin Exp Metastasis 2014 31 4 395 405 10.1007/s10585-014-9635-8 24442969 109 Kast RE Karpel-Massler G Halatsch ME CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib …

Effect of miRNA-19a on gastrointestinal motility in rats with functional dyspepsia.

The effect of microRNA (miRNA)-19a on gastrointestinal motility in rats with functional dyspepsia was investigated. Fifty adult Sprague-Dawley (SD) rats were randomly divided into 5 groups, 10 rats in each group, one group as the normal group, one group as the model group, and the other three groups were divided into negative control group, miRNA-19a mimic group and miRNA-19a inhibitor group. All rats were intraperitoneally injected with miRNA-19a scramble, miRNA-19a mimic and miRNA-19a inhibitor. Except the normal group, the functional dyspepsia model rat was established by proper clipping ta

Совпадение в полном тексте источника
… The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells. Int J Cancer. 2013;132:1751–1760. doi: 10.1002/ijc.27862. 9. Kapeller J, Houghton LA, Mönnikes H, Walstab J, Möller D, Bönisch H, Burwinkel B, Autschbach F, Funke B, Lasitschka F, et al. …

Risk Factors and Impact on Survival of Pathological Fractures in Patients With Humeral Metastasis.

Background Bone metastases often cause pathological fractures and impair patients' quality of life and survival. Although several studies have been conducted on pathological fractures in the femur and spine, limited research has been done on the upper limbs. This study aimed to reveal the risk factors and determine how pathological fractures impact survival in patients with humeral metastasis. Methods This retrospective study was based on patients with humerus metastasis treated in the Nagoya-City University Hospital from 2010 to 2020. Patient characteristics, including sex, age at diagnosis o

Совпадение в полном тексте источника
… with pathological fracture followed up for over 6 months B: Bone Modifying Agents C: Chemotherapy R: Radiotherapy Age (y) | Sex | Primary cancer | Surgery for fracture | Other treatment | Follow up (month) | Range of motion (best) | Analgesics use 73 | Female | Lung | No | R | 20 | No rehabilitation | Celecoxib …

Bracing after percutaneous vertebroplasty for thoracolumbar osteoporotic vertebral compression fractures was not effective.

OBJECTIVE: The objective of this study was to evaluate the effectiveness of bracing after percutaneous vertebroplasty (PVP) for thoracolumbar osteoporotic vertebral compression fractures (OVCF). METHODS: This is a retrospective study where we recruited 138 patients with single-level thoracolumbar OVCF who underwent PVP from January 2018 to March 2018 without bracing after PVP (Group A). The visual analog score (VAS) and vertebral body compression ratio (VCR) were recorded at preoperation, on the second day, at 2 weeks, 1 month, and 6 months after operation. Oswestry Disability Index (ODI) was

Совпадение в полном тексте источника
… These 24 patients were given celecoxib to relieve pain, and the pain was significantly reduced at the last follow-up. There were no significant differences in VAS and ODI between these two subgroups at 2 weeks ( Table 3 ). …

Piperine: From Green Extraction to Clinical Translation-A Review.

BACKGROUND: Piperine has diverse pharmacological and bioenhancing activities, but poor aqueous solubility, variable exposure, interaction liability, and discontinuity across production, formulation, and clinical evaluation limit translation. This review integrates these frequently separated stages. METHODS: A structured narrative PubMed search covered English-language studies published from 1 January 2021 to 27 April 2026, supplemented by ClinicalTrials.gov records checked through 13 June 2026, backward citation searching, and selected earlier seminal studies. Evidence was synthesized by expe

Совпадение в полном тексте источника
… Consequently, this study does not establish an independent analgesic contribution of piperine and should be interpreted as inconclusive evidence for piperine-specific clinical efficacy. 81 At the formulation level, Fitriani et al developed a celecoxib-piperine cocrystal system, demonstrating that piperine … The cocrystal exhibited improved dissolution rate and compressibility compared to pure celecoxib, suggesting improved drug release and potential enhancement of analgesic efficacy. …

N-3 Long-Chain Polyunsaturated Fatty Acids, Eicosapentaenoic and Docosahexaenoic Acid, and the Role of Supplementation during Cancer Treatment: A Scoping Review of Current Clinical Evidence.

This scoping review examines the evidence for n-3 long-chain polyunsaturated fatty acid [LCPUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] supplementation in clinical cancer therapy. A comprehensive literature search was performed to identify relevant clinical intervention studies conducted through August 2020. Fifty-seven unique cancer trials, assessing EPA and/or DHA supplementation pre- or post-treatment, concomitant with neoadjuvant chemotherapy, radiation or surgery, or in palliative therapy were included. Breast, head and neck, gastrointestinal, gastric, colorectal/rect

Совпадение в полном тексте источника
… CNT = 0.36 g EPA + 0.24 g DHA | 6 weeks | N-3 + celecoxib: ↓ CRP; ↑ body weight and hand grip scores improved N-3 alone: ↓ CRP | 2007 [ 52 ] Pancreatic (II–IV) | 26 14 F/12 M | Age = 56 (39–75) Body weight = 66.8 (56.0–75.1) BMI = 23.2 (21.1–27.4) | N/A | EPA only week 1: 1 g week 2: 2 g week 3: 4 g … In advanced lung cancer patients with systemic immune metabolic syndrome (SIMS, defined by presence of cachexia, anorexia, ECOG (Eastern Cooperative Oncology Group) status > 2 and high CRP), the combination of 600 mg EPA + DHA and celecoxib (non-steroidal anti-inflammatory drug) increased body weight …

Application of dendritic cell extracellular vesicles as a valid nanoparticle platform for cancer therapies: a narrative review.

The prevalence of cancers has actually increased during the last few decades, affecting almost all human societies. Despite progress in therapeutic protocols, cancer is still the main cause of global human mortality. Although the advancement of modern immunotherapeutic approaches can increase the survival rate of cancer patients, new modalities are essential for improved therapeutic outcomes. Extracellular vesicles (EVs) are nanosized particles and are used for cell-free approaches instead of direct whole cell-based administration. It has been thought that EVs can reduce the risks and side eff